Trabectedin’s contribution to the treatment of sarcomas

about

Optimal management of sarcomas of the breast: an update.

P2860

Q38194594-46553A13-F2E1-4122-B774-BD1A70909B04

P2860

Trabectedin’s contribution to the treatment of sarcomas

Item

http://www.wikidata.org/entity/Q57570780

description

im Juni 2013 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2013

@uk

name

Trabectedin’s contribution to the treatment of sarcomas

@en

Trabectedin’s contribution to the treatment of sarcomas

@nl

type

Item

label

Trabectedin’s contribution to the treatment of sarcomas

@en

Trabectedin’s contribution to the treatment of sarcomas

@nl

prefLabel

Trabectedin’s contribution to the treatment of sarcomas

@en

Trabectedin’s contribution to the treatment of sarcomas

@nl

P1476

Trabectedin’s contribution to the treatment of sarcomas

@en

P2860

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

A review of trabectedin (ET-743): a unique mechanism of action.

ET-743: a novel agent with activity in soft-tissue sarcomas.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.13.48

http://www.w3.org/2001/XMLSchema#string

P433

sup1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Blay

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23638729

http://www.w3.org/2001/XMLSchema#string

Trabectedin’s contribution to the treatment of sarcomas

about

P2860

P2860

Trabectedin’s contribution to the treatment of sarcomas

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698